Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: behavioral and neurochemical evidence
Jentsch J, Tran A, Taylor J, Roth R. Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: behavioral and neurochemical evidence. Psychopharmacology 1998, 138: 89-95. PMID: 9694531, DOI: 10.1007/s002130050649.Peer-Reviewed Original ResearchConceptsMesolimbic dopamine systemPrefrontal cortexInduced hyperlocomotionDopamine neuronsDopamine releaseNucleus accumbensDopamine systemInjection of phencyclidineMesocorticolimbic dopaminergic neuronsMesolimbic dopamine neuronsVentral tegmental areaCell body regionIbotenic acid lesionsPrefrontal Cortical InvolvementProfound cognitive impairmentGlutamatergic releaseNeurochemical evidenceAcute administrationCortical involvementDopamine utilizationDopaminergic neuronsMesolimbic pathwayTegmental areaAcid lesionsDopaminergic activationElectrophysiological and neurochemical evidence that pindolol has agonist properties at the 5‐HT1A autoreceptor in vivo
Clifford E, Gartside S, Umbers V, Cowen P, Hajós M, Sharp T. Electrophysiological and neurochemical evidence that pindolol has agonist properties at the 5‐HT1A autoreceptor in vivo. British Journal Of Pharmacology 1998, 124: 206-212. PMID: 9630361, PMCID: PMC1565357, DOI: 10.1038/sj.bjp.0701796.Peer-Reviewed Original ResearchConceptsDorsal raphe nucleusWAY-100635Clinical trialsAutoreceptor antagonistNeuronal activityAnaesthetized rat. 2Actions of pindololEffect of pindololOngoing clinical trialsEarly clinical trialsRat. 2Majority of neuronesNeurochemical evidenceRaphe nucleusReceptor antagonistFrontal cortexAgonist propertiesMicrodialysis experimentsTherapeutic efficacyPindololAutoreceptorsAntagonistElectrical activityNeuronesTrials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply